Cited by 119Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes Management and Education

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

Open access
Bolli, Geremia B., Kerr, David, Thomas, Reena, Torlone, Elisabetta, Sola-Gazagnes, Agnès, Vitacolonna, Ester, Selam, Jean Louis, Home, Philip D.·2009·Diabetes Care

Abstract

OBJECTIVE: Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) and multiple daily injections (MDIs) with insulin glargine as basal insulin and mealtime insulin lispro have not been prospectively compared in people naïve to either regimen in a multicenter study. We aimed to help close that deficiency. RESEARCH DESIGN AND METHODS: People with type 1 diabetes on NPH-based insulin therapy were randomized to CSII or glargine-based MDI (both otherwise using lispro) and followed for 24 weeks in an equivalence design. Fifty people were correctly randomized, and 43 completed the study. RESULTS: Total insulin requirement (mean ± SD) at end point was 36.2 ± 11.5 units/day on CSII and 42.6 ± 15.5 units/day on MDI. Mean A1C fell similarly in the two groups (CSII −0.7 ± 0.7%; MDI −0.6 ± 0.8%) with a baseline-adjusted difference of −0.1% (95% CI −0.5 to 0.3). Similarly, fasting blood glucose and other preprandial, postprandial, and nighttime self-monitored plasma glucose levels did not differ between the regimens, nor did measures of plasma glucose variability. On CSII, 1,152 hypoglycemia events were recorded by 23 of 28 participants (82%) and 1,022 in the MDI group by 27 of 29 patients (93%) (all hypoglycemia differences were nonsignificant). Treatment satisfaction score increased more with CSII; however, the change in score was similar for the groups. Costs were ∼3.9 times higher for CSII. CONCLUSIONS: In unselected people with type 1 diabetes naïve to CSII or insulin glargine, glycemic control is no better with the more expensive CSII therapy compared with glargine-based MDI therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc08-1874

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 28 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Bolli, G. B., Kerr, D., Thomas, R., Torlone, E., Sola-Gazagnes, A., Vitacolonna, E., Selam, J. L., & Home, P. D.
Affiliations
  • University of Perugia (IT)
  • Royal Bournemouth Hospital (GB)
  • Newcastle University (GB)
  • Service de Diabétologie, Hôtel Dieu, APHP, Paris, France;
  • University of Chieti-Pescara (IT)
  • Assistance Publique – Hôpitaux de Paris (FR)
Corresponding author
Bolli, Geremia B.
Venue
Diabetes Care
Published
2009-04-23
Volume
32
Issue
7
Pages
1170-1176
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2142372141
Cited by
119
References
28
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 9 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 10 · 2015: 9 · 2014: 6 · 2013: 9 · 2012: 13
FWCI
10.44
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 1 diabetes, insulin pump therapy, multiple daily insulin injections, insulin glargine, insulin lispro, basal insulin, glycemic control, hypoglycemia, insulin requirement, glycemic variability, treatment satisfaction, cost comparison
MeSH terms
Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Kinetics, Male, Middle Aged, Age of Onset, Insulin, Long-Acting, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review